Genzyme

Cambridge, United Stateswww.sanofigenzyme.com1expert edge

Biopharmaceutical company specializing in rare genetic disorders and immunology. Acquired by Sanofi in 2011 for $20.1 billion, representing one of the largest biotech acquisitions.

Why interesting to a deal team

$20B acquisition price demonstrates premium valuations for specialized rare-disease pharma capabilities. Key precedent for PE-backed CDMO rollups and exit strategy benchmarking.

Experts connected to this company

Stuart SmithAdvised Genzyme on its $20B sale to Sanofi

Stuart Smith

Partner, Healthcare Practice

Centerview Partners

BankerNew York

One of the most senior healthcare services bankers on Wall Street, with three decades of pattern-recognition across CDMO, CRO, PBM, and services roll-ups and consolidations.

Sources

No name matchPrimary
sanofigenzyme.com
Page titleOther
npr.org/2011/02/17/133831825/Sanafi-Picks-Up-Genzyme-for-20-Billion

Strongest evidencePage title2 public sourcesHow the grades work